Who makes GSK1605786 500 mg?

GSK1605786 500 mg is developed by GlaxoSmithKline.

What development phase is GSK1605786 500 mg in?

GSK1605786 500 mg is in Phase 1.

Last reviewed 2026-05-14 · How we verify

GSK1605786 500 mg

GlaxoSmithKline · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	GSK1605786 500 mg
Sponsor	GlaxoSmithKline
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects (PHASE1)
A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy Subjects (PHASE1)
Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese Subjects (PHASE1)
A Study to Investigate the Efficacy and Safety of GSK1605786 for Treatment of Patients With Active Ulcerative Colitis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GSK1605786 500 mg CI brief — competitive landscape report
GSK1605786 500 mg updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI